Figure 8From: CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivoChemotherapy decreases cell proliferation in the adult mouse CNS. Systemic exposure to cisplatin and BCNU was associated with profound changes in the number of BrdU-incorporating cells in the lateral SVZ, the DG and the CC. Animals were treated as described in Figure 5. The graphs show the percent-corrected values of BrdU+ cells per brain area normalized to the number of BrdU+ cells in sham-treated animals at various time points after systemic treatment with either BCNU or cisplatin. Data are means ± SEM. (a,b) Percent-corrected values of BrdU+ cells after (a) BCNU treatment or (b) cisplatin treatment. Bars labeled with an asterisk show statistically significant (P < 0.01) differences from control animals. (c) Immunoperoxidase staining for detection of BrdU+ cells in the lateral SVZ in representative sections from a 0.9% NaCl-injected control animal (C), one day (D1), and 42 days (D42) after systemic treatment with BCNU (3 × 10 mg/kg i.p.). (d) Diagrammatic representation of the part of the SVZ shown in (c) with adjacent part of the striatum (STR) and the overlying CC.Back to article page